{"product_id":"teleflex-pestle-analysis","title":"Teleflex PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political shifts, economic pressures, and tech innovation are reshaping Teleflex’s prospects with our concise PESTLE snapshot—designed for investors and strategists who need fast, actionable insight. Buy the full PESTLE to get a detailed, fully editable breakdown of risks and opportunities that you can use in pitches, valuations, or strategic plans. Purchase now for instant download and practical intelligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeleflex's global supply chain—with manufacturing exposure in Asia and Europe—remains sensitive to US-China tariffs and EU trade measures; in 2024 supply-chain costs rose industry-wide, with medical device input prices up about 4–6% year-over-year, pressuring margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reform Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChanges in US and European healthcare systems alter procurement and reimbursement—Medicare Advantage enrollment hit 49% of Medicare beneficiaries in 2024, shifting purchasing power and pressure on margins for device makers like Teleflex (FY2024 revenue $1.8B). Value-based care mandates require outcome data; hospitals tying 20–30% of payments to quality metrics increase demand for demonstrably superior devices. Political shifts in public health budgets (EU health spending 9.8% of GDP on average in 2023) can cause demand volatility for specialized technologies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Harmonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeleflex faces pressure from international bodies pushing for harmonized medical device standards, affecting its global regulatory strategy as the FDA, MDR and China NMPA increasingly coordinate—WHO estimates 50+ countries referencing WHO prequalification by 2024. Political stability in key expansion markets like India and Brazil is critical for approvals and launch timing; India saw a 12% rise in device approvals 2023–24. Divergent national healthcare agendas can raise entry costs and require diplomatic engagement and localized clinical data to meet varying national requirements, often delaying market entry and increasing compliance spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental Pandemic Preparedness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-2020 emphasis on national stockpiles has increased government procurement of respiratory and vascular access devices; US Strategic National Stockpile purchases rose over 40% in 2021–2023, favoring suppliers with surge capacity.\u003c\/p\u003e\n\u003cp\u003ePolicies in 2024–2025 include incentives for domestic medical manufacturing; US CHIPS-like funding and EU reshoring grants boosted local PPE\/DEVICE output by ~25%.\u003c\/p\u003e\n\u003cp\u003eTeleflex must align operations and qualify for domestic-content mandates to capture multi-year government contracts that now represent an estimated 10–15% of hospital procurement spend in emergency preparedness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGovernment procurement growth: +40% (SNS 2021–2023)\u003c\/li\u003e\n\u003cli\u003eDomestic manufacturing boost: ~25% (2024–2025 programs)\u003c\/li\u003e\n\u003cli\u003ePotential contract share: 10–15% of preparedness-related hospital spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTaxation and Fiscal Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorporate tax rates and international tax treaties materially affect Teleflex's after-tax margins and cash repatriation; a 2024 effective tax rate near 16–18% would shift net income and capital allocation toward either R\u0026amp;D or shareholder returns.\u003c\/p\u003e\n\u003cp\u003eChanges to U.S. repatriation rules could unlock hundreds of millions in offshore cash—affecting 2024–25 acquisition funding—while stricter treaty enforcement raises compliance costs.\u003c\/p\u003e\n\u003cp\u003eOngoing political debates over medical device excise taxes (previously 2.3% before pauses) pose downside risk to long-term planning and could reduce gross margins if reinstated.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 estimated effective tax rate: ~16–18%\u003c\/li\u003e\n\u003cli\u003ePotential repatriable offshore cash: hundreds of millions\u003c\/li\u003e\n\u003cli\u003eMedical device excise tax historically 2.3%—reinstatement risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy shocks: tariffs, taxes and procurement squeeze margins despite domestic output gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical factors: trade\/tariff risks (US-China, EU) raised device input costs ~4–6% in 2024; procurement shifts (Medicare Advantage 49% 2024) pressure margins; government stockpiling boosted SNS purchases +40% (2021–23) and domestic manufacturing incentives lifted local output ~25% (2024–25); 2024 effective tax rate ~16–18% and excise tax reinstatement (2.3%) remain downside risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost rise (2024)\u003c\/td\u003e\n\u003ctd\u003e4–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Advantage (2024)\u003c\/td\u003e\n\u003ctd\u003e49%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSNS purchases (2021–23)\u003c\/td\u003e\n\u003ctd\u003e+40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic output boost (2024–25)\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEffective tax rate (2024 est.)\u003c\/td\u003e\n\u003ctd\u003e16–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExcise tax risk\u003c\/td\u003e\n\u003ctd\u003e2.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces uniquely impact Teleflex across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarized Teleflex PESTLE analysis that highlights key political, economic, social, technological, legal, and environmental factors for quick reference in meetings and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising labor, logistics and raw-material costs—medical-grade plastics up ~14% and stainless-steel alloys ~9% year-over-year in 2024—compressed Teleflex’s adjusted EBIT margin, which fell to 18.2% in FY2024; ongoing inflation may force price increases that risk competitive share loss. Teleflex’s cost-savings (lean programs, sourcing) helped, but inflation-driven price passes could reduce volume as hospital purchasing power weakens amid slower healthcare spending in the US and Europe.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a multinational, Teleflex faces material foreign currency translation risk when consolidating into USD; in 2024 roughly 30% of revenue was non‑USD, amplifying sensitivity to exchange swings.\u003c\/p\u003e\n\u003cp\u003eA stronger dollar raises local prices abroad, which can trim volumes in key markets—EMEA and APAC accounted for ~40% of international sales in 2024.\u003c\/p\u003e\n\u003cp\u003eTeleflex uses hedging programs—forwards and options—to limit FX earnings volatility; in 2024 hedges reduced reported currency headwinds by an estimated $25–35 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe prevailing interest rate environment affects Teleflex’s cost of debt and M\u0026amp;A capacity; US 10-year Treasury yields rose to ~4.5% in 2024, pushing borrowing costs higher and increasing interest expense (Teleflex reported net long-term debt of $1.2bn as of FY2023), likely constraining capex and large acquisitions. If rates stabilize or decline toward 3–3.5%, Teleflex could pursue more aggressive expansion and investments in medical-device startups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Capital Spending Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe economic health of hospitals directly affects capital spending on new devices; US hospital operating margins fell to about 1.7% in 2023 and medtech capex growth slowed to low single digits, prompting delays in non-essential projects and constrained purchases of high-end interventional cardiology and surgical tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospital margins ~1.7% (2023)\u003c\/li\u003e\n\u003cli\u003eMedtech capex growth: low single digits (2023–24)\u003c\/li\u003e\n\u003cli\u003eDelayed non-essential projects reduce demand for high-end devices\u003c\/li\u003e\n\u003cli\u003eTeleflex must track hospital financials to forecast product demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic expansion in emerging markets offers Teleflex avenues to grow beyond Western markets; IMF projects 2024–25 growth of 4.1% for emerging and developing economies versus 1.8% for advanced economies, boosting addressable demand.\u003c\/p\u003e\n\u003cp\u003eRising middle classes and healthcare spending—OECD\/World Bank data show healthcare expenditure per capita rising fastest in Asia Pacific—drive demand for advanced devices like Teleflex’s products.\u003c\/p\u003e\n\u003cp\u003eRisks include currency volatility, slower reimbursement cycles, and payment terms; many EMs report higher sovereign debt volatility and longer hospital procurement timelines, potentially pressuring margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIMF 2024 EM growth ~4.1% vs advanced 1.8%\u003c\/li\u003e\n\u003cli\u003eFaster per-capita health spend increase in Asia Pacific (World Bank)\u003c\/li\u003e\n\u003cli\u003eHigher FX and reimbursement risk; longer procurement cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation, FX and tight hospital margins squeeze Teleflex; APAC demand offers relief\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation raised input costs (medical plastics +14%, stainless alloys +9% YoY 2024), squeezing Teleflex’s adjusted EBIT margin to 18.2% in FY2024; hedges cut FX headwinds by ~$25–35m in 2024 while ~30% of revenue was non‑USD, exposing currency risk. US hospital margins ~1.7% (2023) and medtech capex growth low single digits limit device purchases; IMF projects EM growth ~4.1% (2024–25) boosting APAC demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj EBIT margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e18.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical plastics YoY (2024)\u003c\/td\u003e\n\u003ctd\u003e+14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStainless alloys YoY (2024)\u003c\/td\u003e\n\u003ctd\u003e+9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon‑USD revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX hedge benefit (2024)\u003c\/td\u003e\n\u003ctd\u003e$25–35m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospital margin (2023)\u003c\/td\u003e\n\u003ctd\u003e~1.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMF EM growth (2024–25)\u003c\/td\u003e\n\u003ctd\u003e~4.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTeleflex PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Teleflex PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751497314681,"sku":"teleflex-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/teleflex-pestle-analysis.png?v=1772232246","url":"https:\/\/matrixbcg.com\/products\/teleflex-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}